Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
beam therapeutics在Terry-Ann Burrell宣佈計劃於8月9日離職加入摩根大通後，開始尋找新的首席財務官。
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.
生物技術公司Beam Therapeutics Inc. （納斯達克：BEAM）通過鹼基編輯開發精準基因藥物，今天宣佈，其首席財務官Terry-Ann Burrell將於2024年8月9日離開公司，擔任摩根大通投資銀行的副主席一職。作爲過渡的一部分，公司已經啓動尋找繼任者的搜索。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。